Empaa-L tablets combine Empagliflozin 10 mg (an SGLT2 inhibitor) and Linagliptin 5 mg (a DPP-4 inhibitor). It is used to improve blood sugar control in adults with type 2 diabetes, especially when one drug alone is not sufficient. Empagliflozin works by helping the kidneys remove excess glucose via urine. Linagliptin increases the levels of incretin…
Empaa-L 5/25 is a combination oral tablet containing Empagliflozin 25 mg and Linagliptin 5 mg. It is used for improving blood sugar control in adults with type 2 diabetes, especially when one drug alone is insufficient. Empagliflozin helps reduce blood sugar by increasing excretion of glucose via the kidneys. Linagliptin enhances the effect of natural…
Empagli 10 mg contains empagliflozin, an oral medicine for type 2 diabetes. It works by helping the kidneys remove excess glucose through urine. The tablet is taken once daily, with or without food. It helps improve blood sugar control and also supports heart and kidney health in diabetics. Common side effects may include frequent urination,…
Empagli 25 mg tablets contain empagliflozin, a drug for type 2 diabetes. It helps lower blood sugar by making the kidneys excrete excess glucose through urine. The tablet is taken once daily, with or without food. Used when lower doses have not achieved target glycemic control, or in patients needing stronger blood sugar reduction. It…
Empoli 10 mg contains empagliflozin, a drug used for managing type 2 diabetes. It helps reduce high blood sugar by causing the kidneys to remove excess glucose via urine. Usually taken once daily, with or without food. It can also help reduce the risk of heart-related complications in people with diabetes. Common side effects include…
Empoli 25 mg is a tablet whose active ingredient is empagliflozin. It is used to treat type 2 diabetes by helping lower elevated blood sugar levels. The drug works by inhibiting SGLT-2 in the kidneys, increasing glucose excretion in urine. Usually taken once daily, with or without food, under medical supervision. In addition to lowering…
EMSYN 10MG Tablet is an anti-allergic and anti-inflammatory medicine used to relieve allergic conditions, skin rashes, itching, and hay fever. It contains Epinastine 10mg (or similar antihistamine, depending on formulation), which works by blocking histamine receptors, thereby reducing allergy symptoms. It is commonly prescribed for seasonal allergies, urticaria, and other hypersensitivity reactions.
EMSYN 25MG Tablet is an antihistamine medicine used to treat allergic conditions such as hay fever, urticaria (hives), skin rashes, and itching. It contains Epinastine 25mg (or similar antihistaminic agent), which works by blocking histamine receptors, reducing allergic symptoms like redness, swelling, and itching.
EMSYN MET 12.5/1000mg Tablet (14S) is a combination anti-diabetic medicine used to manage type 2 diabetes mellitus. It contains Empagliflozin 12.5mg (which helps lower blood glucose by increasing urinary glucose excretion) and Metformin 1000mg (which reduces glucose production in the liver and improves insulin sensitivity). This combination helps improve blood sugar control when diet, exercise,…
EMSYN MET 12.5/500mg Tablet (14S) is a combination oral anti-diabetic medicine used to manage type 2 diabetes mellitus. It contains Empagliflozin 12.5mg, which lowers blood sugar by promoting glucose excretion through urine, and Metformin 500mg, which reduces hepatic glucose production and improves insulin sensitivity. This combination helps achieve better blood glucose control when diet, exercise,…
ChatGPT said: EMSYN MET 5/1000mg Tablet (14S) is a combination anti-diabetic medicine used to manage type 2 diabetes mellitus. It contains Empagliflozin 5mg, which helps lower blood glucose by increasing urinary glucose excretion, and Metformin 1000mg, which reduces glucose production in the liver and improves insulin sensitivity. This combination helps achieve effective blood sugar control…
In order to provide you a personalized shopping experience, our site uses cookies. By continuing to use this site, you are agreeing to our cookie policy.